NCT02296853View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 22, 2014

Primary Completion Date

April 17, 2015

Study Completion Date

April 17, 2015

Conditions
Hepatitis B Virus
Interventions
DRUG

TAF

25 mg tablet administered orally

Trial Locations (5)

1142

Gratton

32809

Orlando

33014

Miami

78215

San Antonio

D-81241

Munich

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY